- Home
- MDIA vs TVGN Comparison
MDIA vs TVGN Comparison
Compare MDIA & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- TVGN
- Stock Information
- Founded
- MDIA 2019
- TVGN 2020
- Country
- MDIA United States
- TVGN United States
- Employees
- MDIA N/A
- TVGN N/A
- Industry
- MDIA Broadcasting
- TVGN Blank Checks
- Sector
- MDIA Consumer Discretionary
- TVGN Finance
- Exchange
- MDIA Nasdaq
- TVGN Nasdaq
- Market Cap
- MDIA 59.3M
- TVGN 53.6M
- IPO Year
- MDIA N/A
- TVGN N/A
- Fundamental
- Price
- MDIA $1.08
- TVGN $1.46
- Analyst Decision
- MDIA
- TVGN
- Analyst Count
- MDIA 0
- TVGN 0
- Target Price
- MDIA N/A
- TVGN N/A
- AVG Volume (30 Days)
- MDIA 57.4K
- TVGN 15.4M
- Earning Date
- MDIA 11-26-2024
- TVGN 11-29-2024
- Dividend Yield
- MDIA N/A
- TVGN N/A
- EPS Growth
- MDIA N/A
- TVGN N/A
- EPS
- MDIA N/A
- TVGN N/A
- Revenue
- MDIA $69,296,000.00
- TVGN N/A
- Revenue This Year
- MDIA N/A
- TVGN N/A
- Revenue Next Year
- MDIA N/A
- TVGN N/A
- P/E Ratio
- MDIA N/A
- TVGN N/A
- Revenue Growth
- MDIA 94.96
- TVGN N/A
- 52 Week Low
- MDIA $0.40
- TVGN $0.26
- 52 Week High
- MDIA $6.86
- TVGN $21.09
- Technical
- Relative Strength Index (RSI)
- MDIA 34.76
- TVGN 47.99
- Support Level
- MDIA $1.11
- TVGN $1.01
- Resistance Level
- MDIA $1.34
- TVGN $1.91
- Average True Range (ATR)
- MDIA 0.11
- TVGN 0.36
- MACD
- MDIA 0.00
- TVGN -0.11
- Stochastic Oscillator
- MDIA 3.23
- TVGN 23.56
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.